A Review: Cytochrome P450 in Alcoholic and Non-Alcoholic Fatty Liver Disease
Yu-Jie Jiang,Ye-Ming Cao,Yong-Bing Cao,Tian-Hua Yan,Cheng-Lin Jia,Ping He
DOI: https://doi.org/10.2147/dmso.s449494
2024-04-02
Diabetes Metabolic Syndrome and Obesity Targets and Therapy
Abstract:Yu-Jie Jiang, 1, 2 Ye-Ming Cao, 1 Yong-Bing Cao, 1 Tian-Hua Yan, 2 Cheng-Lin Jia, 1 Ping He 1 1 Institute of Vascular Anomalies, Shanghai Academy of Traditional Chinese Medicine, Shanghai, 200082, People's Republic of China; 2 Department of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, 211100, People's Republic of China Correspondence: Cheng-Lin Jia; Ping He, Institute of Vascular Anomalies, Shanghai Academy of Traditional Chinese Medicine, Shanghai, 200082, People's Republic of China, Tel/Fax +1 522 136 9352 ; +1 301 693 1191, Email ; Alcoholic fatty liver disease (FALD) and non-alcoholic fatty liver disease (NAFLD) have similar pathological spectra, both of which are associated with a series of symptoms, including steatosis, inflammation, and fibrosis. These clinical manifestations are caused by hepatic lipid synthesis and metabolism dysregulation and affect human health. Despite having been studied extensively, targeted therapies remain elusive. The Cytochrome P450 (CYP450) family is the most important drug-metabolising enzyme in the body, primarily in the liver. It is responsible for the metabolism of endogenous and exogenous compounds, completing biological transformation. This process is relevant to the occurrence and development of AFLD and NAFLD. In this review, the correlation between CYP450 and liver lipid metabolic diseases is summarised, providing new insights for the treatment of AFLD and NAFLD. Keywords: CYP450, liver metabolism, lipid accumulation, monooxygenases, alcoholic fatty liver disease, non-alcoholic fatty liver disease Liver metabolism disorders are primarily caused by an imbalance in lipid metabolism, which leads to the excessive accumulation of triglycerides (TG) and cholesterol (CHOL) in the liver. In addition, fatty metamorphosis induces liver inflammation and oxidative stress (OS), leading to cellular dysfunction, necrosis, and liver fibrosis. If untreated, cirrhosis develops and/or liver failure may occur. 1 The global prevalence of hepatic lipid metabolism diseases is 32.4%, posing a huge burden on global health. 2,3 Cytochrome P450 (CYP450) monooxygenases are abundant in the liver and essential for the metabolism of endogenous and exogenous compounds, including fatty acids. Thus, CYP450 serves as a novel target for the prevention and treatment of hepatic lipid metabolic diseases. 4 Here, we summarised what is known about the relationship between hepatic CYP450 and lipid metabolism disorders. CYP450 belongs to a multifunctional redox superfamily. 5 The discovery of it in rat liver microsomes dates back to 1958. 6 In its reduced state, CYP450 maximum absorption peaks at 450 nm, which is the reason for its name. 7 The CYP cDNA encodes 420–560 amino acids with a molecular weight of approximately 50 kDa, and has a conserved structural fold. 8 CYP nomenclature is based on their sequence similarity, with a cut-off of 40% defining a family member and 55% or more defining a subfamily member. 9 There are 18 known families and 43 known subfamilies of CYP450. 10 Among them, the CYP1, 2, and 3 families are the most abundant in the human liver, accounting for approximately 70% of the total hepatic CYP450 content. 11 CYP450 is widely distributed in the human body, and differential spectroscopy can detect its expression in various organs, 12 including the liver, intestine, pancreas, brain, lungs, adrenal glands, kidneys, bone marrow, mast cells, skin, ovary and testis; however, experimental tests revealed that it is mainly expressed in the liver. 13 In addition, the distribution of CYP450 in the liver is also different. For example, CYP1A is mainly expressed in the hepatocytes surrounding the small hepatic veins, 14 while CYP3A is preferentially expressed in hepatocytes in the central area of the hepatic lobular. 15 CYP450 is mainly distributed in the endoplasmic reticulum and mitochondrial inner membrane. 16 It has a unique structure and is one of the most versatile biocatalysts in nature. CYP450 metabolises exogenous compounds, including drugs, ensuring their efficacy and controlling toxicity. 11 Additionally, it catalyses endogenous substrates, including arachidonic acids, estradiol, cholesterol, vitamin D, and neurotransmitters. 17 Its structure consists of 12 α helices and antiparallel β-folds, 18 and is divided into cytosolic domain (CD), transmembrane domain (TD) and coheme, which is the source of CYP450 catalytic activity. 19 Heme achieves electron transfer through the protoporphyrin structure 20 (Fe 3+ is located in the center of the site and bin -Abstract Truncated-
endocrinology & metabolism